menu ☰
menu ˟

Adalimumab biosimilar safe, effective in RA

29 Dec 2017
Patients with rheumatoid arthritis who were treated with SB5, an adalimumab biosimilar, demonstrated a comparable response rate to those who received adalimumab, as judged by the American College of Rheumatology 20% improvement criteria, according to...

Click here to view the full article which appeared in Rheumatology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.